이 페이지는 자동 번역되었으며 번역의 정확성을 보장하지 않습니다. 참조하십시오 영문판 원본 텍스트의 경우.

진행된 고형 종양에서의 PHST001에 대한 연구

2026년 9월 30일 업데이트: Pheast Therapeutics

개방형-라벨, 1A/1B, 용량 에스컬레이션 및 용량 확장 연구, 진보 된 재발 및/또는 내화성 고형 종양을 가진 성인 환자에서 PHST001의 안전, 약동학, 약력학 및 항 종양 활성을 조사하는 연구.

This is a multi-center, first-in-human (FIH), open-label, Phase 1a/1b dose escalation and dose expansion study to assess the safety, PK, pharmacodynamics, and antitumor activity of PHST001 monotherapy (Phase 1a) or in combination with anticancer therapies (Phase 1b) in adult participants with advanced relapsed and/or refractory solid tumors (including but not limited to CNS tumors in Phase 1a only). Phase 1b will include the following cohorts 1) tumor-specific cohorts for participants with advanced relapsed and/or refractory ovarian cancer, endometrial cancer, and cholangiocarcinoma, 2) a randomized cohort for participants with ovarian cancer who will receive PHST001 in combination with mirvetuximab soravtansine, 3) a cohort for participants with advanced/metastatic breast cancer who will receive PHST001 in combination with trastuzumab deruxtecan and 4) a cohort of patients who consent to additional biomarker studies.

The study's primary objectives are to evaluate the safety and tolerability of PHST001 and determine the RP2D (Recommended Phase 2 dose) of PHST001 as monotherapy and in combination with anticancer therapies, as well as to assess the anti-tumor activity of PHST001 in combination with anticancer therapies in Phase 1b.

연구 개요

연구 유형

중재적

등록 (추정된)

426

단계

  • 1단계

연락처 및 위치

이 섹션에서는 연구를 수행하는 사람들의 연락처 정보와 이 연구가 수행되는 장소에 대한 정보를 제공합니다.

연구 연락처

  • 이름: Raphaël Rousseau, Chief Medical Officer, PhD, MD
  • 전화번호: 650-260-8443
  • 이메일: medical@pheast.com

연구 장소

    • California
      • Beverly Hills, California, 미국, 90212
      • Los Angeles, California, 미국, 90033
      • Palo Alto, California, 미국, 94304
        • 모병
        • Stanford University School of Medicine
        • 연락하다:
        • 수석 연구원:
          • Oliver Dorigo, MD, PhD
    • Colorado
      • Denver, Colorado, 미국, 80218
        • 모병
        • Sarah Cannon Research Institute (SCRI) Oncology Partners - Denver Health One
        • 연락하다:
    • Connecticut
      • New Haven, Connecticut, 미국, 06520
        • 모병
        • Yale Cancer Center
        • 수석 연구원:
          • Michael Cecchini, MD
        • 연락하다:
    • Illinois
      • Chicago, Illinois, 미국, 60637
        • 모병
        • University of Chicago Medical Center
    • Massachusetts
    • Michigan
      • Ann Arbor, Michigan, 미국, 48109
        • 모병
        • University of Michigan Rogel Cancer Center
        • 수석 연구원:
          • Ulka Vaishampayan, MD
        • 연락하다:
      • Grand Rapids, Michigan, 미국, 49546
        • 모병
        • START Center for Cancer Research - Midwest
        • 수석 연구원:
          • Sreenivasa Chandana, MD, PhD
        • 연락하다:
    • New York
      • Lake Success, New York, 미국, 11042
        • 모병
        • START Center for Cancer Research - Long Island New York
        • 수석 연구원:
          • Geraldine O'Sullivan Coyne, MD
        • 연락하다:
      • New York, New York, 미국, 10029
        • 모병
        • Mount Sinai
        • 수석 연구원:
          • Thomas Marron, MD, PhD
        • 연락하다:
    • North Carolina
      • Durham, North Carolina, 미국, 27710
    • Tennessee
      • Nashville, Tennessee, 미국, 37203
        • 모병
        • Vanderbilt-Ingram Cancer Center
        • 연락하다:
          • Clinical Trials Office (CTO)
          • 전화번호: 1-800-811-8480
          • 이메일: cip@vumc.org
        • 수석 연구원:
          • Elizabeth Davis, MD, PhD
      • Nashville, Tennessee, 미국, 37203
        • 모병
        • Sarah Cannon Research Institute (SCRI) Oncology Partners
        • 수석 연구원:
          • Deepak Bhamidipati, MD
        • 연락하다:
    • Texas
      • Fort Worth, Texas, 미국, 76104
        • 모병
        • START Center for Cancer Research - Texas
        • 연락하다:
        • 수석 연구원:
          • Henry Xiong, MD, PhD
      • Houston, Texas, 미국, 77030
        • 모병
        • MD Anderson Cancer Center
        • 연락하다:
        • 수석 연구원:
          • Stéphane Champiat, MD, PhD
      • Irving, Texas, 미국, 75039
        • 모병
        • NEXT Oncology - Dallas
        • 수석 연구원:
          • Michael Song, MD, PhD, PharmD
        • 연락하다:
      • San Antonio, Texas, 미국, 78229
        • 모병
        • University of Texas (UT) Health
        • 수석 연구원:
          • Daruka Mahadevan, MD, PhD
        • 연락하다:
      • San Antonio, Texas, 미국, 78229
        • 모병
        • START Center for Cancer Research - San Antonio
        • 수석 연구원:
          • Kyriakos Papadopoulos, MD
        • 연락하다:
    • Virginia

참여기준

연구원은 적격성 기준이라는 특정 설명에 맞는 사람을 찾습니다. 이러한 기준의 몇 가지 예는 개인의 일반적인 건강 상태 또는 이전 치료입니다.

자격 기준

공부할 수 있는 나이

18년 이상 (성인, 고령자)

건강한 자원 봉사자를 받아들입니다

아니

연구 대상 성별

모두

설명

Key Inclusion Criteria:

  • Histologically or cytologically confirmed advanced solid tumor which has relapsed from or been refractory to all locally available standard therapies.
  • Adequate organ function per laboratory testing
  • Pregnancy prevention requirements
  • Measurable disease per RECIST v1.1 (or RANO) as assessed by the local site Investigator/radiology
  • Performance status of 0 or 1 on Eastern Cooperative Oncology Group (ECOG) scale

Key Exclusion Criteria:

  • Diagnosis of immunodeficiency
  • History of a previous additional malignancy, unless potentially curative treatment has been completed, with no evidence of malignancy for 2 years. Participants with basal cell carcinoma of the skin, Stage I melanoma, melanoma in situ, squamous cell carcinoma of the skin, early-stage prostate cancer, low grade neoplasms, or carcinoma in situ, excluding carcinoma in situ of the bladder, who have undergone potentially curative therapy are not excluded and can be enrolled regardless of disease-free period following completion of potentially curative therapy. Participants with early-stage breast cancer who have undergone curative intent treatment and with no disease recurrence for 2 years after treatment are not excluded.
  • Active known CNS metastases and/or carcinomatous meningitis from a systemic (non-CNS) primary malignancy. Participants with previously treated CNS metastases are eligible, provided they are radiologically and clinically stable (i.e., no evidence of progression for at least 2 weeks by repeat imaging performed during screening) and are not requiring systemic corticosteroids above the physiologic replacement for at least 7 days prior to the first dose of study treatment.
  • Received prior systemic anticancer therapy including investigational agents within 21 days or, if shorter, within 5 half-lives prior to the first dose of study treatment. Participants must have recovered from all AEs due to previous therapies to Grade ≤1 or baseline. Participants with Grade ≤2 neuropathy may be eligible. Participants with endocrine-related AEs Grade ≤2 requiring treatment or hormone replacement may be eligible.
  • Prior autologous or allogeneic hematopoietic stem cell transplant or solid organ transplant.
  • Received previous treatment with another agent targeting CD24.

공부 계획

이 섹션에서는 연구 설계 방법과 연구가 측정하는 내용을 포함하여 연구 계획에 대한 세부 정보를 제공합니다.

연구는 어떻게 설계됩니까?

디자인 세부사항

  • 주 목적: 치료
  • 할당: 무작위
  • 중재 모델: 순차적 할당
  • 마스킹: 없음(오픈 라벨)

무기와 개입

참가자 그룹 / 팔
개입 / 치료
실험적: PHST001 Monotherapy

Participants will receive PHST001 monotherapy administered once every 3 weeks (Q3W). In Phase 1a, PHST001 will be evaluated in sequential dose-escalation cohorts at planned dose levels of 0.1, 0.3, 1.0, 2.0, 4.0, 6.0, 9.0, 18.0, and 36.0 mg/kg. Dose levels may be modified or additional dose levels evaluated based on emerging safety, pharmacokinetic, pharmacodynamic, and antitumor activity data. Participants in the Phase 1b biomarker cohort may also receive PHST001 monotherapy.

PHST001 is an anti-CD24 macrophage checkpoint inhibitor, administered as IV infusions every 3-weeks (Q3W) dosing intervals.

실험적: PHST001 + Paclitaxel

Participants will receive PHST001 in combination with paclitaxel. The combination will initially be evaluated in a Phase 1b safety run-in group. Following safety clearance, the combination may be evaluated in tumor-specific expansion cohorts, including participants with ovarian carcinoma, endometrial carcinoma, or cholangiocarcinoma, and/or in the biomarker cohort.

PHST001 is an anti-CD24 macrophage checkpoint inhibitor, administered as IV infusions every 3-weeks (Q3W) dosing intervals.

Paclitaxel used as per standard of care.

다른 이름들:
  • 탁솔
실험적: PHST001 + Topotecan

Participants will receive PHST001 in combination with topotecan. The combination will initially be evaluated in a Phase 1b safety run-in group. Following safety clearance, the combination may be evaluated in the ovarian carcinoma expansion cohort and/or biomarker cohort.

PHST001 is an anti-CD24 macrophage checkpoint inhibitor, administered as IV infusions every 3-weeks (Q3W) dosing intervals.

Topotecan used as per standard of care.

다른 이름들:
  • 하이캄틴
실험적: PHST001 + Doxorubicin

Participants will receive PHST001 in combination with doxorubicin. The combination will initially be evaluated in a Phase 1b safety run-in group. Following safety clearance, the combination may be evaluated in ovarian carcinoma or endometrial carcinoma expansion cohorts and/or the biomarker cohort.

PHST001 is an anti-CD24 macrophage checkpoint inhibitor, administered as IV infusions every 3-weeks (Q3W) dosing intervals.

Doxorubicin used as per standard of care.

다른 이름들:
  • 아드리아마이신
실험적: PHST001 + FOLFIRI

Participants will receive PHST001 in combination with FOLFIRI (5-fluorouracil, folinic acid, and irinotecan). The combination will initially be evaluated in a Phase 1b safety run-in group. Following safety clearance, the combination may be evaluated in the cholangiocarcinoma expansion cohort and/or biomarker cohort.

PHST001 is an anti-CD24 macrophage checkpoint inhibitor, administered as IV infusions every 3-weeks (Q3W) dosing intervals.

FOLFIRI used as per standard of care.

다른 이름들:
  • folinic acid (leucovorin), fluorouracil (5-FU), and irinotecan combination
실험적: PHST001 + FOLFOX

Participants will receive PHST001 in combination with FOLFOX (5-fluorouracil, folinic acid, and oxaliplatin). The combination will initially be evaluated in a Phase 1b safety run-in group. Following safety clearance, the combination may be evaluated in the cholangiocarcinoma expansion cohort and/or biomarker cohort.

PHST001 is an anti-CD24 macrophage checkpoint inhibitor, administered as IV infusions every 3-weeks (Q3W) dosing intervals.

FOLFOX used as per standard of care.

다른 이름들:
  • folinic acid (leucovorin), fluorouracil (5-FU), and oxaliplatin combination
실험적: PHST001 + Gemcitabine

Participants will receive PHST001 in combination with gemcitabine. The combination will initially be evaluated in a Phase 1b safety run-in group. Following safety clearance, the combination may be evaluated in ovarian carcinoma or cholangiocarcinoma expansion cohorts and/or the biomarker cohort.

PHST001 is an anti-CD24 macrophage checkpoint inhibitor, administered as IV infusions every 3-weeks (Q3W) dosing intervals.

Gemcitabine used as per standard of care.

다른 이름들:
  • 젬자
실험적: PHST001 + Mirvetuximab Soravtansine

Participants will receive PHST001 in combination with mirvetuximab soravtansine. The combination will initially be evaluated in a Phase 1b safety run-in group. Following safety clearance, the combination may be evaluated in the ovarian carcinoma expansion cohort and/or in the biomarker cohort. Half of the participants in the randomized ovarian carcinoma cohort may be randomly assigned to receive PHST001 in combination with mirvetuximab soravtansine.

PHST001 is an anti-CD24 macrophage checkpoint inhibitor, administered as IV infusions every 3-weeks (Q3W) dosing intervals.

Mirvetuximab soravtansine used as per standard of care.

다른 이름들:
  • MIRV, Elahere
실험적: PHST001 + Trastuzumab Deruxtecan

Participants will receive PHST001 in combination with trastuzumab deruxtecan. The combination will initially be evaluated in a Phase 1b safety run-in group. Following safety clearance, the combination may be evaluated in participants with advanced or metastatic breast cancer and/or in the biomarker cohort.

PHST001 is an anti-CD24 macrophage checkpoint inhibitor, administered as IV infusions every 3-weeks (Q3W) dosing intervals.

Trastuzumab deruxtecan used as per standard of care.

다른 이름들:
  • T-DXd, 엔허투
활성 비교기: Mirvetuximab Soravtansine Monotherapy

Participants with ovarian carcinoma enrolled in the randomized Phase 1b expansion cohort will be randomized 1:1 to receive mirvetuximab soravtansine monotherapy or mirvetuximab soravtansine in combination with PHST001. Participants assigned to this arm will receive mirvetuximab soravtansine monotherapy.

Mirvetuximab soravtansine used as per standard of care.

다른 이름들:
  • MIRV, Elahere

연구는 무엇을 측정합니까?

주요 결과 측정

결과 측정
측정값 설명
기간
Frequency of Dose-Limiting Toxicities (DLTs) to assess the safety and tolerability of PHST001 as monotherapy (Phase 1a) or in combination with anticancer therapy (Phase 1b)
기간: From first dose of PHST001 through 21 days after the first dose of PHST001

Based on toxicities observed

From first dose of PHST001 through 21 days after the first dose of PHST001
Frequency of Serious Adverse Events (SAEs) to assess the safety and tolerability of PHST001 as monotherapy (Phase 1a) or in combination with anticancer therapy (Phase 1b)
기간: From signed consent up to 90 days after the last dose of PHST001

Based on toxicities observed

From signed consent up to 90 days after the last dose of PHST001
Frequency of Treatment Emergent Adverse Events (TEAEs) to assess the safety and tolerability of PHST001 as monotherapy (Phase 1a) or in combination with anticancer therapy (Phase 1b)
기간: From first dose up to 90 days after the last dose of PHST001

Based on toxicities observed

From first dose up to 90 days after the last dose of PHST001
Frequency of Treatment Related Adverse Events (TRAEs) to assess the safety and tolerability of PHST001 as monotherapy (Phase 1a) or in combination with anticancer therapy (Phase 1b)
기간: From first dose up to 90 days after the last dose of PHST001

Based on toxicities observed

From first dose up to 90 days after the last dose of PHST001
Frequency of Adverse Events of Special Interest (AESIs) to assess the safety and tolerability of PHST001 as monotherapy (Phase 1a) or in combination with anticancer therapy (Phase 1b)
기간: From first dose up to 90 days after the last dose of PHST001

Based on toxicities observed

From first dose up to 90 days after the last dose of PHST001
Frequency of AEs Leading to Dose Interruption or Treatment Discontinuation and AEs Leading to Death to assess the safety and tolerability of PHST001 as monotherapy (Phase 1a) or in combination with anticancer therapy (Phase 1b)
기간: From first dose up to 90 days after the last dose of PHST001

Based on toxicities observed

From first dose up to 90 days after the last dose of PHST001
Overall Response Rate (ORR) based on RECIST v1.1 to assess the preliminary antitumor activity of PHST001 in combination with anticancer therapy (Phase 1b non-randomized cohorts only)
기간: From screening and during treatment up to 2 years

Defined as the proportion of subjects with confirmed complete response (CR) or partial response (PR); a confirmed response is a response that persists on repeat-imaging ≥ 4 weeks after initial documentation of response.

From screening and during treatment up to 2 years
Progression-Free Survival (PFS) based on RECIST v1.1 to assess the preliminary antitumor activity of PHST001 in combination with anticancer therapy (Phase 1b randomized cohort only)
기간: From screening and during treatment up to 2 years

Defined as the time from first dose of PHST001 to first documentation of radiographic disease progression or death, whichever occurs first.

From screening and during treatment up to 2 years

2차 결과 측정

결과 측정
측정값 설명
기간
Overall Response Rate (ORR) based on RECIST v1.1 (or RANO for primary CNS Tumors) to assess the preliminary antitumor activity of PHST001 as monotherapy (Phase 1a) and in combination with anticancer therapy (Phase 1b - randomized cohort only)
기간: From screening and during treatment up to 2 years

Defined as the proportion of subjects with confirmed complete response (CR) or partial response (PR); a confirmed response is a response that persists on repeat-imaging ≥ 4 weeks after initial documentation of response.

From screening and during treatment up to 2 years
Duration of Response (DOR) based on RECIST v1.1 (or RANO for primary CNS Tumors) to assess the preliminary antitumor activity of PHST001 as monotherapy (Phase 1a) and in combination with anticancer therapy (Phase 1b)
기간: From screening and during treatment up to 2 years

Defined as time from date of first objective response (either CR or PR) to first documentation of radiographic disease progression.

From screening and during treatment up to 2 years
Best Overall Response (BOR) based on RECIST v1.1 (or RANO for primary CNS Tumors) to assess the preliminary antitumor activity of PHST001 as monotherapy (Phase 1a) and in combination with anticancer therapy (Phase 1b)
기간: From screening and during treatment up to 2 years

Defined as the best response recorded for a participant across all time-point assessments from the start of treatment until disease progression or end of treatment.

From screening and during treatment up to 2 years
Progression-Free Survival (PFS) based on RECIST v1.1 (or RANO for primary CNS Tumors) to assess the preliminary antitumor activity of PHST001 as monotherapy (Phase 1a) and in combination with anticancer therapy (Phase 1b - non-randomized cohorts only) .
기간: From screening and during treatment up to 2 years

Defined as the time from first dose of PHST001 to first documentation of radiographic disease progression or death, whichever occurs first.

From screening and during treatment up to 2 years
Overall Survival (OS) based on RECIST v1.1 (or RANO for primary CNS Tumors) to assess the preliminary antitumor activity of PHST001 as monotherapy (Phase 1a) and in combination with anticancer therapy (Phase 1b).
기간: From screening and during treatment up to 2 years

Defined as the time from first dose of PHST001 to the date of death.

From screening and during treatment up to 2 years
Maximum Observed Concentration (Cmax) to characterize the serum PK of PHST001 as monotherapy (Phase 1a) or in combination with anticancer therapy (Phase 1b).
기간: From treatment until 90 days after last dose of PHST001

Defined as the maximum blood concentration of a dose of PHST001

From treatment until 90 days after last dose of PHST001
Time to Maximum Concentration (tmax) to characterize the serum PK of PHST001 as monotherapy (Phase 1a) or in combination with anticancer therapy (Phase 1b)
기간: From treatment until 90 days after last dose of PHST001

Defined as the time required for a dose of PHST001 to reach its maximum blood concentration (Cmax) after administration.

From treatment until 90 days after last dose of PHST001
Concentration at the End of a Dosing Interval (Ctrough) to characterize the serum PK of PHST001 as monotherapy (Phase 1a) or in combination with anticancer therapy (Phase 1b)
기간: From treatment until 90 days after last dose of PHST001

Defined as the blood concentration of a dose of PHST001 at the end of the dosing interval (just prior to next drug administration).

From treatment until 90 days after last dose of PHST001
Area Under the Concentration-time Curve (AUC) to characterize the serum PK of PHST001 as monotherapy (Phase 1a) or in combination with anticancer therapy (Phase 1b)
기간: From treatment until 90 days after last dose of PHST001

Defined as the total PHST001 exposure over time, calculated as the integral of the plasma concentration-time profile.

From treatment until 90 days after last dose of PHST001
Volume of Distribution at Steady-state (Vss) to characterize the serum PK of PHST001 as monotherapy (Phase 1a) or in combination with anticancer therapy (Phase 1b)
기간: From treatment until 90 days after last dose of PHST001

Defined as how widely PHST001 spreads throughout the body once things have stabilized after a dose has been administered.

From treatment until 90 days after last dose of PHST001
Clearance (CL) to characterize the serum PK of PHST001 as monotherapy (Phase 1a) or in combination with anticancer therapy (Phase 1b)
기간: From treatment until 90 days after last dose of PHST001

Defined as the rate at which the body "cleans out" a dose of PHST001 from the bloodstream.

From treatment until 90 days after last dose of PHST001
Terminal Elimination Half-life (t½) to characterize the serum PK of PHST001 as monotherapy (Phase 1a) or in combination with anticancer therapy (Phase 1b)
기간: From treatment until 90 days after last dose of PHST001

Defined as the time it takes for the amount of PHST001 in the body to drop by half during the final phase of elimination.

From treatment until 90 days after last dose of PHST001

공동 작업자 및 조사자

여기에서 이 연구와 관련된 사람과 조직을 찾을 수 있습니다.

연구 기록 날짜

이 날짜는 ClinicalTrials.gov에 대한 연구 기록 및 요약 결과 제출의 진행 상황을 추적합니다. 연구 기록 및 보고된 결과는 공개 웹사이트에 게시되기 전에 특정 품질 관리 기준을 충족하는지 확인하기 위해 국립 의학 도서관(NLM)에서 검토합니다.

연구 주요 날짜

연구 시작 (실제)

2025년 3월 31일

기본 완료 (추정된)

2029년 4월 1일

연구 완료 (추정된)

2031년 4월 1일

연구 등록 날짜

최초 제출

2025년 2월 10일

QC 기준을 충족하는 최초 제출

2025년 2월 18일

처음 게시됨 (실제)

2025년 2월 21일

연구 기록 업데이트

마지막 업데이트 게시됨 (실제)

2026년 10월 5일

QC 기준을 충족하는 마지막 업데이트 제출

2026년 9월 30일

마지막으로 확인됨

2026년 9월 1일

추가 정보

이 연구와 관련된 용어

추가 관련 MeSH 약관

기타 연구 ID 번호

  • PHST001-101

약물 및 장치 정보, 연구 문서

미국 FDA 규제 의약품 연구

예

미국 FDA 규제 기기 제품 연구

아니

이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .

구독하다